In a groundbreaking initiative, Australia’s Southern Cross University is spearheading a study to examine the effectiveness of medicinal cannabis in alleviating symptoms of Fibromyalgia Syndrome (FMS). This condition, affecting roughly 2.7% of the global populace, manifests as widespread pain, fatigue, and sleep disturbances, with limited treatment options currently available.

The study, supported by Little Green Pharma and conducted at Griffith University’s Clinical Trial Unit in Queensland, aims to recruit 36 participants by December 20. It seeks to build upon previous research indicating the potential benefits of medical cannabis for fibromyalgia patients, particularly in pain reduction and enhancing life quality.

Dr Janet Schloss, the Principal Investigator, emphasizes the importance of patient participation to deepen understanding of medicinal cannabis’s safety and efficacy in treating this complex disorder. The study requires participants to have a formal fibromyalgia diagnosis and a referral from their healthcare professional.

Little Green Pharma is providing a balanced THC: CBD medicinal cannabis oil and a placebo for the study. This Phase 2 trial is a randomized, double-blinded, placebo-controlled clinical trial, co-supervised by Dr Leon Warne, LGP’s Head of Research & Innovation. Dr Warne highlights the critical need for patient involvement to further comprehend the clinical benefits of medicinal cannabis.

For more details and participation guidelines, visit Southern Cross University’s study page.